positive blood cultures. Two blood cultures drawn from separate sites will be positive for the same organism in at least 99% of patients with bacterial endocarditis.
The Duke criteria have been widely used in diagnosing both NVE and PVE. 5 Most authors have found the criteria to be sensitive and specific. This combines clinical, echocardiographic, and microbiologic data to guide the clinician in assessing the likelihood of PVE. 5 The foundation of the treatment of PVE is antibiotic therapy, and a significant percentage of patients require surgery as well. The principles for antibiotic therapy outlined by Cowgill and colleagues 4 are: bactericidal antibiotics should be used; therapy should include two drugs that have synergistic bactericidal efficacy against the pathogen, in vitro susceptibility testing to ensure that bactericidal; drug levels are achieved, and antibiotic therapy should be administered for at least 6 to 8 weeks. Blood cultures should become negative within 3 to 5 days of antibiotic therapy initiation, and they should continue to be negative for at least 1 month after completion of antibiotic therapy. Anticoagulation should be considered for thrombus formation with subsequent embolization. 6, 7 The incidence of embolization is markedly reduced by antibiotic therapy.
The indications for surgery in PVE are failure of medical management. They include heart failure, uncontrolled infection, prosthetic valve dysfunction, heart block, recurrent embolism, and infectious organism (fungus, gram negative bacteria). Approximately 50% of patients undergo surgery during active phase of the disease (early surgery) because of disease severity. 8 On the day of admission (07/10/2013), examination of the patient showed pulse rate of 90 bpm,regular; B.P.=100/60 mmHg, temperature =102R"F, mildly anaemic, no cyanosis, jaundice or oedema, mild dehydration, metallic sound found during auscultation of the heart, breath sound decreased in basal area of both lungs. His abdomen was distended, tense and tender. Bowel sound present, urine color was high.
Treatment started with IV broad spectrum antibiotics like Ceftriaxone, Amikacin, Metronidazole, and Cap. Fluconazole. Fever subsided after 3 days. But fever back again on 5 th day so IV Meropenem was started.
But despite all management patient expired on 16/10/2013. He was discharged with oral medications on 9/11/2013 after complete recovery. Patient was advised for follow up after one week.
Discussion:
Both cases presented here are early PVE as duration of symptoms development were within 60 days. Both the case present with high grade fever, malaise, anaemia,features of heart failure and there was leukocytosis which was sine qua non for PVE.
In first patient, there were impaired renal function tests including proteinuria, hematuria, pus cell in urine. He also had impaired hepatic functions too. INR was high. Prompt initiation of multiple broad spectrum intravenous antibacterial agents,oral anti-fungal agents doneeven though the culture and sensitivity results of blood and urine showed no growths. Fever reduced for some duration but it relapsed and septicemia developed. Patient became hemodynamically unstable in spite of inotropic support and patient expired.
Second patient was also treated with antibacterial and antifungal agents. Fever subsided and patient improved.
There was no plan for surgical intervention as echocardiograph showed no paravalvular leakage or any thrombus on the valve leaflets or heart chambers.
Infective endocarditis (IE) is the most serious complications of the valve replacement. Prosthetic valve endocarditis (PVE) accounted for over 20% of all IE cases reflecting a considerably higher proportion of IE compared with earlier reports. 1 Despite improvement in medical treatment and surgery, prosthetic valve endocarditis carries a high mortality risk ranging from 20 to 80 % of affected patients. In addition, the best treatment strategy for these patients is still debated. Although a surgical strategy is said to be the best treatment option, guidelines based on prospective randomized studies are still lacking and some authors claim that medical treatment can be sufficient for some patients. 9 Our patient was improved within a short period of time. So our treatment is supported by some other study. 9 By the centers for Disease Control and Prevention definitions, an infection involving an implanted prosthetic device within the first 12 months of an operative procedure is considered to be a nosocomial infection and more likely to be acquired at the time of operation. 10 A causal relationship between health care contact and PVE has been inferred and well described for PVE occurring within 60 days of valve implantation. Initial reports estimated that early PVE accounted for approximately 35% to 50% of all the cases of PVE and noted its association with gram-positive microorganisms (particularly coagulasenegative staphylococci and S. aureus) presumed to be nosocomial in origin. 1 Early PVE accounted with an extremely high mortality rate. This lower rate of early PVE was similar to other recent reports and may be related to a number of factors, including improvements in surgical techniques, hygiene, and infection control. 1 In a previous investigation, Calderwood et al 1 reported that the cumulative hazard of developing PVE was highest within the initial 12 months after valve replacement surgery. Our results confirm that the first year after implantation is a vulnerable period for prosthetic valve infection with both S. aureus and coagulase-negative staphylococci. Possible explanations for the time course of health care associated PVE include greater exposure to health care contact and lack of complete endothelialization of the prosthetic valve early after implantation. 1 Although PVE was diagnosed promptly and treated commonly with surgical intervention, the morbidity and in-hospital mortality rates were very high. 1 Staphylococcus aureusand health care associated infection were found to be independently predictive of in hospital mortality. 1 The strongest predictors of mortality were well-recognized complications of PVE: persistent bacteremia, as well as health care associated infection, has been found to be independently associated with S. aureus IE. 1 Fungi are important causes of prosthetic valve endocarditis; they are responsible for 9.6% of early cases and for 4.3 %of late cases. 11 C. albicans is the most common fungal pathogen, accounting for 10-15% of all cases of prosthetic valve endocarditis. 11 Open-heart surgery is a predisposing factor for fungal for fungal endocarditis. 11 When blood cultures are negative but symptoms and signs of endocarditis are noted following prosthetic valve replacement,fungal prosthetic valve endocarditis with surgical replacement of the involved valves, followed by anti-fungal therapy. It is noteworthy that there have been several reports of patients successfully treated with antifungal therapy alone. 11 Surgical treatment of prosthetic valve endocarditis has evolved in the direction of increasingly radical debridement of infected tissue and reconstruction with biological materials. Previously published experience of 146 patients operated on for prosthetic valve endocarditis (including 46 patients with EO-PVE) between 1975 and 1992 showed 5-year survival was 71%, with subsequent reoperations performed for 15% of in-hospital survivors. 10 In conclusion, PVE accounts for a high percentage of all cases of IE in many regions of the world. Prosthetic valve endocarditis continues to carry a high mortality rate, ranging from 20% to 80%, depending on the series. 12 There are no prospective, randomized studies that have compared medical and surgical therapy, and these two therapeutic strategies should be viewed as complementary. Despite prompt diagnosis and the common use of surgical treatment in PVE, morbidity and mortality remain high, emphasizing the need for further studies of preventive and therapeutic strategies for this serious disease.
